 The Food and Drug Administration on Monday approved Biogens Alzheimers disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living with Alzheimers and the first new medicine for the disease in nearly two decades. CNBCs Jim Cramer, Carl Quintanilla and David Faber discuss. 